Journal Article10.1530/EOR-21-0083
Current concepts from diagnosis to management in Gorham–Stout disease: a systematic narrative review of about 350 cases
TL;DR: A narrative review of GSD etiopathology highlights current standards in diagnosis, clinical management and therapeutic strategies, and multi-targeted pharmacological approach includes innovative options.
read more
Abstract: Patients with Gorham–Stout disease (GSD) present progressive destruction and resorption of bone. Typical bone-related symptoms include swelling, pain and functional impairment in the region involved. The three aspects of GSD etiopathology are osteoclasts, angiogenesis/lymphangiogenesis and osteoblast function. Multi-targeted pharmacological approach includes innovative options and represent milestones of treatment, sometimes associated with radiotherapy. Surgery is mainly used to treat complications: pathologic/impending fractures, spinal instability or deformities and chylothorax. In this narrative review, we highlight current standards in diagnosis, clinical management and therapeutic strategies.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Chylothorax Associated with the Syndrome of Idiopathic Osteolysis Including Gorham–Stout Disease: Spontaneous Remission Without Treatment
Sota Monma,Michihiro Yano,Masazumi Matsuda,Hiroyuki Tsuchie,Naoko Mori +4 more
Case Report and Literature Review: Bisphosphonate, Sirolimus, and Atenolol Treatment in a 4-Year-Old Child Diagnosed with Gorham–Stout Disease
Su Jin Park,Jae Won Yoo,Moon Bae Ahn +2 more
TL;DR: The triple combination treatment with bisphosphonate, sirolimus, and atenolol may be helpful in stabilizing the disease course of GSD.
The Genetic Architecture of Vascular Anomalies: Current Data and Future Therapeutic Perspectives Correlated with Molecular Mechanisms
Lăcrămioara Butnariu,Eusebiu Vlad Gorduza,Laura Florea,Elena Tarca,Stefana Maria Moisa,Laura Mihaela Trandafir,Simona Stoleriu,Minerva Codruta Badescu,Alina Costina Luca,Setalia Popa,Iulian Radu,Elena Cojocaru +11 more
TL;DR: The results revealed that the phenotypic variability of VAs is correlated with genetic heterogeneity, and the identification of new genetic factors and the molecular mechanisms in which they intervene, will allow the development of modern therapies that act targeted as a personalized therapy.
References
Propranolol for Severe Hemangiomas of Infancy
Christine Léauté-Labrèze,Dumas de la Roque E,Thomas Hubiche,Franck Boralevi,Thambo Jb,Alain Taieb +5 more
TL;DR: It is observed in 11 children that propranolol can inhibit the growth of infantile capillary hemangiomas and this work is hopeful that this discovery will help improve the prognosis of these patients.
2.3K
Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman disease.
Adrien Flahault,Marguerite Vignon,Marion Rabant,Aurélie Hummel,Laure-Hélène Noël,Danielle Canioni,Bertrand Knebelmann,Felipe Suarez,Khalil El Karoui +8 more
TL;DR: Although rare, this diagnosis is worth knowing, as specific treatment has to be started as soon as possible and proved to be efficient in this case as well as in other reports in the literature.
1.9K
Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis.
L. Gorham,Arthur Purdy Stout +1 more
TL;DR: There now exists the basis for a new syndrome supported by a remarkable similarity of clinical and roentgenographic findings in twenty-four cases, and by an equally convincing similarity of the histological picture in eight of these, which the author has personally studied.
659
Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway
Asiri R. Wijenayaka,Masakazu Kogawa,Hui Peng Lim,Lynda F. Bonewald,David M. Findlay,Gerald J. Atkins +5 more
TL;DR: It is suggested that sclerostin may have a catabolic action through promotion of osteoclast formation and activity by osteocytes, in a RANKL-dependent manner.
Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption
Shumpei Niida,Masato Kaku,Hitoshi Amano,Hisahiro Yoshida,Hiroshi Kataoka,Satomi Nishikawa,Kazuo Tanne,Norihiko Maeda,Shin-Ichi Nishikawa,Hiroaki Kodama +9 more
TL;DR: It is demonstrated that M-CSF and VEGF have overlapping functions in the support of osteoclastic bone resorption in op/op mice with a deficiency in osteoclasts resulting from a mutation in M- CSF gene.